Repositorio Institucional en Ciencias de la Salud de la Región Murcia

The co-inheritance of two ITGB3 variants with additive detrimental effects on platelets leads to variant Glanzmann thrombasthenia.

2026-03-06T14:27:00Z

The co-inheritance of two ITGB3 variants with additive detrimental effects on platelets leads to variant Glanzmann thrombasthenia. Arndt, Nina; Falcinelli, Emanuela; Zamora-Cánovas, Ana; Sánchez-Fuentes, Ana; Marín-Quílez, Ana; Nieto-Hernández, María-Del-Mar; Rivera, José; Gresele, Paolo; Bury, Loredana

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

2026-03-06T14:26:59Z

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study. Rodríguez-Veiga, Rebeca; Gil, Cristina; Sobas, Marta; Torres-Miñana, Laura; Botella-Martínez, Carmen; de-la-Serna, Javier; Bernal, Teresa; Salamero, Olga; Otero, Cristina; Navarro-Vicente, Irene; de-Miguel, Carlos; Garrido, Ana; Vives, Susana; Bergua, Juan; Pérez-Encinas, Manuel; Algarra, Lorenzo; González-Campos, José; Caballero-Gómez, María-del-Mar; Prates, María-Virginia; Benavente, Celina; Tormo, Mar; Cervera, Marta; Fazio, Patricia; Amutio, María-Elena; García, Raimundo; Pomares, Helena; Vidriales, Belén; Serrano, Josefina; Amigo, María-Luz; Rubio, Vicente; Almela, Agata; Barrios, Manuel; Sossa-Melo, Claudia-Lucía; Paluszewska, Monika; Novo, Andrés; Gromek, Tomasz; Rodríguez-Macias, Gabriela; Oleksiuk, Jolanta; Lloret-Madrid, Pilar; Montesinos, Pau Acute promyelocytic leukemia (APL) is a highly curable leukemia characterized by life-threatening coagulopathy leading to hemorrhagic and thrombo-ischemic events. We analyzed the incidence, outcomes and risk-factors of thromboischemic events in a large series of 1210 patients with newly diagnosed APL reported to the PETHEMA registry. Therapy consisted on ATRA and chemotherapy (AIDA-based). Median age of patients was 46 years (range 2-90 years). Fifty-eight patients (5%) did not start AIDA regimen as they were unfit for chemotherapy, or they died early before initiating ATRA. A total of 195 (16%) patients developed thrombo-ischemic events, the most frequent being superficial-vein and/or central catheter-related (6.9%) followed by central nervous system (2.2%), deep-vein thrombosis (2.1%), pulmonary embolism (2.1%), acute myocardial infarction (1.6%), or other locations (1.2%). Thromboischemic events mostly occurred at diagnosis and during induction (4.0%, and 9.3%, respectively). Patients developing life-threatening thrombo-ischemic events (i.e, excluding superficial and/or catheter-related) at diagnosis/induction had 31% early death rate. Prolonged aPTT, age >40 years, ECOG more than 1, platelets > 25 x 109/L, and absence of bleeding at presentation were independent risk factors for life-threatening thrombo-ischemic events. Using these variables (1 point each) we developed and validated the Thromb-On risk score, identifying a high-risk group (3 to 5 points). The Thromb-On risk score was validated in a cohort of 585 patients treated since 2017 with arsenic trioxide plus ATRA (<10x109 leukocytes) or AIDA (?10x109 leukocytes). This study could help to improve prevention and management of life-threatening thromboischemic events, through risk-adapted guidance, potentially leading to decrease early mortality in APL.

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries

2026-03-06T14:26:58Z

Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries Moulis, Guillaume; Chen, Frederick; Carli, Giuseppe; Ghanima, Waleed; Trautmann-Grill, Karolin; Stauch, Thomas; Schifferli, Alexandra; Miah, Haroon; Rueter, Manuela; Ghiotto, Lisanna; Tomasello, Riccardo; Georgi, Annabell; Mcdonald, Vickie; Zaja, Francesco; Pettersen, Heidi-Hassel; Kuhne, Thomas; Lozano-Almela, María-Luisa; González-López, Tomas-Jose; Provan, Drew; Michel, Marc; Cooper, Nichola; Rodeghiero, Francesco

Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding

2026-03-06T14:26:57Z

Cancer-related thrombosis: impact of biological sex on the risk of rethrombosis and bleeding García-Adrián, Silvia; Iglesias-Pérez, Claudia; Carmona-Bayonas, Alberto; Ortega-Morán, Laura; Pérez, Jaime-Rubio; Martínez-del-Prado, Purificación; Martínez-de-Castro, Eva; Neria, Fernando; Fernández-Pérez, Isaura; García-de-Herreros, Marta; Carmona-Campos, Marta; García-Escobar, Ignacio; Balanya, Rut-Porta; Marrupe-González, David; Jiménez-Fonseca, Paula; Guirao-García, María-Esperanza; Sánchez-Cánovas, Manuel; Muñoz-Langa, José; Pérez-Segura, Pedro; Méndez-Vidal, M-José; Muñoz-Martín, Andrés-Jesús Patients with cancer have a higher risk of re-thrombosis and bleeding secondary to anticoagulant treatment than have individuals without cancer. Given the lack of specific clinical trials, the decision regarding the optimal duration of treatment must consider multiple factors, including sex. The current study used data from the international, prospective TESEO Registry that includes consecutive patients diagnosed with cancer-associated thrombosis. Between July 2018 and December 2022, 2,823 patients were included in the TESEO Registry, 1,351 (48%) of whom were female. The most common venous thromboembolic event (VTE) in both sexes was pulmonary embolism, with an incidence of 58.0% among men and 54.3% in women (P=0.045). After a median follow-up of 6.9 months (interquartile range, 1.9-14.4), the re-thrombosis rate at the end of follow-up was 10.0% in males and 15.0% in females (P=0.14). The location of the primary tumor in the gastrointestinal tract was associated with a greater risk of re-thrombosis, whereas sex had no significant impact. Men had twice as many major bleeds. Additional risk factors for major bleeding included situations of risk due to tumor site or thrombocytopenia, as well as the presence of active tumor bleeding at the time of VTE diagnosis. Overall survival was longer among women. Given the higher incidence of major bleeding among men, sex should be deemed a relevant factor when deciding the duration of anticoagulant treatment in cancer patients.